HAL vs LYEL · P/E 9.3, $19.05B cap vs rev $61.0K
Halliburton Company (HAL) versus Lyell Immunopharma Inc (LYEL) — a side-by-side from cached financials, not a winner call.
Halliburton Company (HAL) is a oil & gas equipment & services company listed on US.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
HAL does not have a complete income-statement cache yet.
Latest reported LYEL revenue for 2024-12-31 was $61.0K. Net income was -$343.0M. Revenue was down 53.1% from 2023-12-31 to 2024-12-31. LYEL currently screens at market cap $143.5M.
HAL currently screens at market cap $19.05B and trailing P/E 9.3. LYEL currently screens at market cap $143.5M.
Not investment advice. Open the HAL and LYEL stock pages for the full models.
Not investment advice.